The relationship between hepatitis B virus (HBV) infection and lipid accumulation remains largely unknown. In this study, we investigated the effect of HBV propagation on lipid droplet growth in HBV-infected cells and HBV-producing cell lines, HepG2.2.15 and HBV-inducible Hep38.7-Tet. The amount of intracellular triglycerides was significantly reduced in HBVinfected and HBV-producing cells compared with HBV-lacking control cells. Electron and immunofluorescent microscopic analyses showed that the average size of a single lipid droplet (LD) was significantly less in the HBV-infected and HBVproducing cells than in the HBV-lacking control cells. Cell death-inducing DFF45-like effectors (CIDEs) B and C (CIDEB and CIDEC), which are involved in LD expansion for the improvement of lipid storage, were expressed at a significantly lower level in HBV-infected or HBV-producing cells than in HBV-lacking control cells, while CIDEA was not detected in those cells regardless of HBV production. The activity of the CIDEB and CIDEC gene promoters was impaired in HBV-infected or HBVproducing cells compared to HBV-lacking control cells, while CIDEs potentiated HBV core promoter activity. The amount of HNF4a, that can promote the transcription of CIDEB was significantly lower in HBV-producing cells than in HBV-lacking control cells. Knockout of CIDEB or CIDEC significantly reduced the amount of supernatant HBV DNA, intracellular viral RNA and nucleocapsid-associated viral DNA, while the expression of CIDEB or CIDEC recovered HBV production in CIDEB-or CIDEC-knockout cells. These results suggest that HBV regulates its own viral replication via CIDEB and CIDEC.
INTRODUCTION
Hepatitis B virus (HBV), which is classified in the Hepadnaviridae family and carries an incomplete double-stranded DNA genome [1] , has infected about 350 million people worldwide via blood-borne and sexual contact, and leads to the development of cirrhosis or hepatocellular carcinoma [2] . Half of the liver cancer cases worldwide are thought to be caused by chronic HBV infection [3] . However, the mechanism by which persistent HBV infection causes hepatocellular carcinoma still remains obscure. Understanding the effect of HBV infection on hepatocytes is required for the development of effective therapy and prevention.
Several reports have associated HBV proteins with dysfunction of the lipid metabolism in cultured cells and mouse models. The expression of HBV X protein (HBx) enhanced the transcriptional activity of SREBP1 and PPARg or the expression of liver fatty acid-binding protein 1, resulting in lipid accumulation in hepatocytes [4, 5] . In addition, HBx potentiated the expression of ACSL4 and accelerated lipogenesis via the impairment of miR-205 transcription in hepatoma cells [6] . Fatty acid accumulation stabilized HBx through reactive oxygen species and Ca 2+ signalling, contributing to the expression of liver inflammatory genes [7] . HBV preS2 also promoted glycolysis and lipid biosynthesis through the activation of ATP citrate lyase in a mouse model and hepatoma cells [8] . However, there is a possibility that the ectopic expression of each viral protein emphasizes its own minor activity. In contrast, the clinical aspects of the relationship between persistent HBV infection and lipid accumulation disagree with those in vitro studies. Wong et al. reported that HBV infection is associated with a lower prevalence of fatty liver, irrespective of HBV genotype [9] . A meta-analysis deduced from the histology of hepatitis B livers suggested that liver steatosis is correlated with host metabolic factors, but negatively associated with the amount of HBV DNA [10] . Hepatitis B was inversely associated with fatty liver diseases, especially in older and obese patients [11] . A recent study regarding a large cohort of healthy adults indicated that HBV infection is associated with a lower risk of developing non-alcoholic fatty liver diseases [12] . Thus, the question of whether HBV production can alter lipid storage in the liver, or is associated with liver steatosis, has not yet been conclusively answered.
A lipid droplet (LD) is composed of triglycerides (TG) and cholesterol esters, surrounded by a lipid monolayer of phospholipid and proteins. The expansion of LD by fusion is a key process in the stabilization of lipid storage. The protein family of cell death-inducing DFF45-like effectors (CIDEs) can play a physiologically important role in LD fusion, promoting TG accumulation and inhibiting lipolysis [13] . The CIDE proteins, comprising A (CIDEA), B (CIDEB) and C (CIDEC; CIDE-3/Fsp27), are the main regulators of LD fusion rather than apoptosis in mice and humans [14] [15] [16] [17] . CIDEA is highly expressed in brown and white adipose tissues [18] . CIDEB is slightly expressed in various tissues and highly expressed in the liver and small intestine [19] . CIDEC is mainly expressed in white adipose tissue, but is not detected in the liver [20] . Deficiency in CIDEA and CIDEC promoted lipolysis [17, 21] , while enhancement of their expression impaired lipolysis [21, 22] . Mice deficient in CIDEC or human patients carrying CIDEC mutations showed reduction in fat mass, formation of small multilocular LDs and protection of diet-induced obesity and insulin resistance [15, 16] . CIDEB-null mice exhibited lower levels of plasma TG and free fatty acids and showed resistance to high-fat diet-induced obesity and liver steatosis [14] . In addition, CIDEB was reported to be involved in the lipidation and maturation of very-low-density lipoprotein (VLDL) by binding apoB-100/-48 and transferring TG into LDs to VLDL precursor [23] . Several recent reports suggested that CIDEB function is associated with the propagation of hepatitis C virus (HCV). CIDEB was reported to be responsible for the entry and assembly of HCV [24, 25] , whereas CIDEB exhibited antiviral activity against HCV [26] . CIDEB may play an important role in HCV propagation or host defence against HCV. However, the effects of CIDE family proteins on HBV production remain unknown.
In this study, we evaluated the amount of TG and observed the morphological features of LDs in HBV-producing cells. Moreover, we investigated the correlation between the CIDE protein family and HBV propagation in order to clarify the effect of HBV production on lipid storage.
RESULTS

Effect of HBV production on LD growth
We first investigated the effect of HBV production on the amount of TG. The HepG2.2.15 cell line, which was prepared from the parental cell line HepG2, carries covalently closed circular DNA (cccDNA) and produces the infectious viral particles [27] . The parental cell line HepG2 was used as the HBV-lacking cell line against the HepG2.2.15 cell line in this study. The Hep38.7-Tet cell line is the HBV-inducible cell line that can permit HBV propagation in the absence of tetracycline [28] . Hep38.7-Tet cells were cultivated for 1 month in medium lacking tetracycline in order to prepare HBV-producing cells, while Hep38.7-Tet cells were cultivated in the presence of tetracycline for use as HBV-lacking cells. TG was prepared from these cell groups and evaluated as described in the Methods section. The amount of TG was significantly lower in the HepG2.2.15 and HBV-induced Hep38.7-Tet cells (HBV-producing cells) than in the HepG2 and HBV-lacking Hep38.7-Tet cells (HBV-lacking cells) (Fig. 1) . LDs are responsible for the main component of TG storage [13] .
Next, we investigated the effect of HBV production on LD size. LDs were stained with BODIPY558/568 C 12 and observed using a confocal laser-scanning microscope. LDs were smaller in HepG2.2.15 cells than in HepG2 cells (Fig. 2a) . The total area and number of LDs and the cell number (nuclear number) in each field of view were quantified using Image-J software. The total area occupied by LDs was smaller in a single HBV-producing cell than in a single HBV-lacking cell (Fig. S1a, b ) available in the online Supplementary Material), although the effect of HBV production on the number of LD in a single cell was subtle or not significantly changed (Fig. S1a, b) . The average area occupied by a single LD was calculated based on those values. The average size occupied by a single LD was significantly smaller in the HepG2.2.15 cell line than in HepG2 (Fig. 2b) . Furthermore, individual LDs were observed under an electron microscope. We prepared ultra-thin sections with the fixed monolayer cells to avoid any artificial effect of centrifugation on cell structures. When HepG2.2.15 and HepG2 cells were observed at 25 000Â magnification, the LDs had oval shapes and seemed to be smaller in the HepG2.2.15 cells than in the HepG2 cells (Fig. 2c) . The average size occupied by a single LD was calculated from the evaluated values and was significantly less in HepG2.2.15 cells than in HepG2 cells (Fig. 2d) from cell clonality. Thus, the size occupied by a single LD was evaluated using the HBV-inducible cell line Hep38.7-Tet. HBV HBc antigen was detected in most of the HBVproducing Hep38.7-Tet cells, but not in HBV-lacking Hep38.7-Tet cells (Fig. 3a) . The average area occupied by a single LD was significantly smaller in HBV-producing cells than in HBV-lacking cells (Fig. 3b ), in agreement with the results in Fig. 2 . When HBV-producing and HBV-lacking cells were observed by transmission electron microscopy, the average size occupied by a single LD was significantly less in HBV-producing cells than in the control cells (Fig. 3c, d ). These results suggest that HBV production reduces the LD size.
We next examined the effect of the viral genotype on TG accumulation and LD size. Huh7-OK1 cells were transfected with the empty plasmid (pUC19) or the plasmid containing the 1.3 mer HBV genome of genotype A, B or C. HBs and HBe antigens were detected in the culture supernatants of HBV-transfected cells, but not in that of the control cells (Fig. S2a) . The amount of TG was significantly lower in HBV-transfected cells than the control cells (Fig. S2b) . The average size occupied by a single LD was significantly less in HBV-transfected cells than in the control cells (Fig. S2c) . The data suggest that HBV production reduces the LD size and TG accumulation irrespective of the viral genotype.
Effect of HBV production on the expression of CIDE proteins LDs grow larger through LD-LD membrane fusion, which is mainly regulated by CIDE proteins [13] . We next examined the effect of HBV production on expression of CIDE proteins. The amounts of CIDEA, CIDEB and CIDEC were evaluated by semi-quantitative RT-PCR. Expressions of CIDEB and CIDEC, but not CIDEA, were detected in the HepG2 and HepG2.2.15 cells (Fig. 4a ). The amounts of CIDEB and CIDEC were quantitatively reduced in the HepG2.2.15 cell line compared with HepG2 cells (Fig. 4a, b) . Furthermore, CIDEB and CIDEC mRNAs were expressed at lower levels in HBV-producing Hep38.7-Tet cells than in HBV-lacking control cells (Fig. 4c, d ), while CIDEA was not detected in Hep38.7-Tet cells regardless of HBV production ( Fig. 4c ).
Hep38.7-Tet cells were seeded to a culture plate in the presence of tetracycline. The medium was exchanged 24 h after cell seeding with fresh medium containing or lacking tetracycline (day 0). When HBV production was induced by a lack of tetracycline, HBs antigen was detected from 5 days post-induction (Fig. 5a ). Intracellular HBV RNA was also increased from 5 days post-induction (Fig. 5b ). CIDEB and CIDEC were significantly decreased at transcriptional levels from days 8 and 5 post-induction, respectively ( Fig. 5c, d ). Furthermore, HBV production also impaired the expression of CIDEB and CIDEC irrespective of the viral genotype ( reduced by siHBV transfection (Fig. S3a-c) , indicating that HBV knockdown was successful. HBV knockdown restored the expression of CIDEB and CIDEC in HepG2.2.15 cells (Fig. S3d) . These results suggest that HBV production impairs the expression of CIDEB and CIDEC.
Effect of HBV production on the promoter activity of CIDEB and CIDEC genes We examined the effect of HBV production on the promoter activities of CIDEB and CIDEC genes. The plasmids encoding these promoters were transfected to the HBV-lacking control (ÀHBV) or the HBV-producing (+HBV) cells. The promoter activity of the CIDEB or CIDEC genes was approximately 5 to 10 times lower in the HBV-producing Hep38.7-Tet cells than in the HBV-lacking control cells (Fig. 6a, left) . The promoter activity of the CIDEB or CIDEC genes was also more than 10 times lower in the HepG2.2.15 cells than in the HepG2 cells (Fig. 6a, right) . These data suggest that HBV production suppresses the promoter activity of CIDEB and CIDEC genes. HNF4a was reduced in HBV-producing cells (Fig. 6b) , although PPARg was increased slightly by HBV production (Fig. 6b) . A reduction in HNF4a may impair CIDEB expression via HBV production.
Effect of HBV infection on LD size and the expression of CIDE proteins An HepG2 cell line expressing NTCP was established for HBV infection, as in our previous report [29] . HBV RNA was detected at 9 to 15 days post-infection (Fig. S4a) . The levels of CIDEB and CIDEC mRNAs were significantly decreased in HBV-infected cells compared with the mock control (Fig. S4b) . HBV-infected cells and uninfected cells (mock) were transfected with the reporter plasmid for cidebor cidec-promoter activity to investigate the effect of HBV infection on cideb-or cidec-promoter activity. HBe antigen was detected in HBV-infected cells but not in the mock control (Fig. S4c) . The promoter activity of the CIDEB or CIDEC genes was significantly reduced in HBV-infected cells compared with the mock cells (Fig. S4d) . We next examined the effect of HCV infection on LD size. The size occupied by a single LD was reduced by HBV infection (Fig.  S4e ). These data suggest that HBV infection impairs the expression of CIDEs via downregulation of cideb and cidec promoters and reduces LD size.
Impact of loss or gain of CIDEB or CIDEC on HBV production We next investigated the loss-and gain-of-function of CIDE proteins in HBV production. The plasmid encoding FLAG-CIDEB or FLAG-CIDEC was transfected into HepG2.2.15 cells. FLAG-CIDEB or FLAG-CIDEC was detected in the cells (Fig. 7a) . Overexpression of FLAG-CIDEB or FLAG-CIDEC significantly enhanced the amounts of supernatant viral DNA and intracellular viral RNA (Fig. 7b, c) . We prepared a CIDEB-deficient HepG2.2.15 cell line and a CIDECdeficient HepG2.2.15 cell line using the CRISPR/Cas9 system. The deleted regions were determined by direct sequence (Fig. 8a) . CIDEB and CIDEC were not detected in CIDEBdeficient cells and CIDEC-deficient cells, respectively (Fig. 8b) . The amounts of supernatant viral DNA and intracellular viral RNA were significantly reduced in CIDEB-deficient cells and CIDEC-deficient cells compared with the wild type HepG2.2.15 cell line (Fig. 8c, d ). Southern blotting analysis showed that the amount of nucleocapsid HBV DNA was reduced in CIDEB-deficient cells and CIDEC-deficient cells (Fig. 8e) . Production of HBs antigen was significantly impaired in CIDEB-deficient cells and CIDEC-deficient cells (Fig. 8f) . Furthermore, HBV production was recovered in CIDEB-deficient cells and CIDEC-deficient cells by the expression of CIDEB and CIDEC, respectively (Fig. 8g) . We next examined the effect of CIDEs on HBV core promoter activity. The plasmid encoding firefly luciferase under the control of HBV core promoter was prepared to estimate the HBV core promoter activity [30] . The reporter plasmid was transfected with the plasmid encoding CIDEB or CIDEC into Huh7-OK1 cells. The resulting cells were then harvested at 48 h post-transfection. Expression of CIDEB or CIDEC significantly promoted the activity of the HBV core promoter (Fig. S5) . These results suggest that CIDEB and CIDEC positively regulate HBV production.
DISCUSSION
In this study, we investigated the effect of HBV production on lipid storage and LD size. The total amount of TG was significantly decreased in HBV-producing cells compared with HBV-lacking cells (Fig. 1) . Electron or fluorescent microscopic observations showed that the average size occupied by a single LD was less in HBV-producing cells than in HBVlacking cells (Figs 2, 3 and S4 ). CIDEs were reported to play a physiologically important role in LD fusion, promoting TG accumulation and inhibiting lipolysis [13] . Our data also indicate that CIDEB and CIDEC positively regulate LD size. CIDEB and CIDEC were decreased in HBV-producing cells (Figs 3, 4, 5 and S4). Overexpression of CIDEB or CIDEC potentiated HBV production (Fig. 7) , while deficiency in CIDEB or CIDEC impaired HBV production and reduced the size of a single LD in HepG2.2.15 cells (Figs 8, Fig. S6a ). Furthermore, expression of CIDEB or CIDEC restored LD size in HBV-producing cells (Fig. S6b) . These data suggest that impairment of CIDE expression stabilizes an appropriate degree of HBV production and curbs an excess of HBV production. CIDEB was detected at the highest level in liver, but CIDEC was not [19, 20] . In this study, HBV production was impaired at 11 days post-induction, compared with the amount of HBV RNA at 8 days post-induction (Fig. 5b) . This corresponded to the lowest level of CIDEB rather than that of CIDEC (Fig. 5c, d ), suggesting that HBV production may affect the expression of CIDEB rather than CIDEC in hepatocytes in vivo. CIDEs significantly promoted the activity of HBV core promoter (Fig. S5 ). CIDEs may interact with an unknown transcription factor to activate the viral promoter [31] . Balance between CIDEs and HBV production may contribute to mild reduction in LD size in HBV-producing cells.
HNF4a and PPARg transcriptionally promote expression of CIDEB and CIDEC, respectively, in hepatocytes [32] [33] [34] [35] . Wu et al. reported that endogenous HNF4a was expressed at a lower level in HepG2.2.15 cells than in HepG2 cells [36] , consistent with our data in Fig. 6b . HBV production may impair expression of HNF4a, resulting in impairment of CIDEB expression. PPARg was significantly lower at a transcriptional level in peripheral blood mononuclear cells of patients with chronic hepatitis B than in those of healthy controls, due to methylation of PPARg promoter regions [37] . However, the data in Fig. 6 show that the amount of PPARg was gradually increased by HBV production, suggesting that CIDEC is transcriptionally downregulated by the PPARg-independent pathway in HBV-producing cells.
The clinical relationship between chronic HBV infection and lipid accumulation in the liver has not yet been clarified. Wong et al. reported that HBV was associated with a lower prevalence of fatty liver, hyperglyceridaemia and metabolic syndrome, irrespective of the HBV DNA level and genotypes [9] . In addition, a study on a Korean cohort suggested that HBV infection was negatively associated with hypertriglyceridaemia and metabolic syndrome [38] . Moreover, Jinjuvadia et al. reported an inverse relationship between chronic HBV infection and metabolic syndrome, including waist circumference, low level of HDL and impaired fasting glucose [39] . Nissin et al. reported the gene expression profiles of liver tissue from HBV-related acute liver failure and normal liver donors for orthotropic liver transplantation as the control group [40] . None of the normal donors had lines of evidence exhibiting infection with hepatitis A, B, C and D or other known viral infections. The complete microarray datasets deposited at the Gene Expression Omnibus database (accession no. GSE38941) indicated that the amount of CIDEB was decreased in the livers of HBV-positive patients. Thus, the clinical aspects of the inverse relationship between liver steatosis and HBV infection may be due to HBVdependent downregulation of CIDEB. Further study will be required for clarification of the relationship between chronic HBV infection and lipid biosynthesis.
In conclusion, the data in this study suggest that HBV production impairs LD expansion and the expression of CIDE proteins, and that CIDE proteins positively regulate HBV production. Downregulation of CIDE proteins might be involved in the optimum level of HBV production to avoid aberrant tissue damage and host immune system for persistent infection. HepG2-NTCP/A3, which is permissive to HBV infection, was established previously [29] . These cells were cultured in collagen-coated dishes and maintained in Dulbecco's Modified Eagle's Medium (DMEM; Sigma, St Louis, MO, USA), supplemented with 10 % foetal bovine serum (FBS; Sigma), 1 % sodium pyruvate (Sigma) and 1 % non-essential amino acid solution (Sigma) at 37 C in the presence of 5 % CO 2 and under humid conditions. The Hep38.7-Tet cell line was derived from the HepAD38 cell line as the clone expressing HBV at the highest level [28, 41] . The Hep38.7-Tet cells were cultivated at 37 C in humid conditions with 5 % CO 2 in DMEM/F-12 (Sigma) supplemented with 10 % FBS, 100 U ml À1 penicillin, 100 µg ml À1 streptomycin (Gibco, Life Technologies, Tokyo, Japan), 18 µg ml À1 hydrocortisone (Sigma), 5 µg ml À1 insulin (Wako, Osaka, Japan), 400 µg/ml G418 (Nacalai Tesque, Kyoto, Japan) and 400 ng ml À1 tetracycline. The production of HBV was induced in the Hep38.7-Tet cell line by incubation in the medium lacking tetracycline. The medium was replaced with fresh medium once every 3 days. Hep38.7-Tet cells maintained in the medium lacking tetracycline for 1 month were used as the HBV-producing cells, while Hep38.7-Tet cells cultivated in the presence of 400 ng ml À1 tetracycline were used as an HBV-lacking control.
METHODS
Cell lines
Virus infection HBV (genotype D) was prepared from the culture supernatant of the Hep38.7-Tet cell line. The culture supernatant was filtrated through a 0.45 µm filter and concentrated using Vivaspin 100K (GE Healthcare Life Sciences, Uppsala, Sweden). [29] . HepG2-NTCP/A3 cells were infected with HBV according to the method reported previously [29] .
Immunofluorescence microscopy The cells were grown on cover slips coated with 0.1 mg ml À1 collagen. LDs were stained by incubation with 1 µg ml À1 BODIPY558/568 C 12 (Molecular Probes, Life Technologies) at 37 C for 60 min. The stained cells were washed once with PBS, fixed with 4 % paraformaldehyde at room temperature for 15 min, and then incubated in PBS for 5 min at room temperature. The resulting cells were permeabilized with PBS containing 0.03 % saponin for 10 min, blocked with PBS containing 0.05 % Tween 20 and 3 % bovine serum albumin (3 % BSA-PBST), and then incubated with anti-HBV preS1 antibody (sc-57764; Santa Cruz, Paso Robles, CA) or anti-HBc antibody [29] at 4 C overnight. The resulting cells were washed three times with PBS and then reacted with 3 % BSA-PBST containing 2 µg ml À1 Alexa Fluor 488-conjugated goat anti-mouse IgG (Molecular Probes, Life Technologies). Nuclei were counterstained with DAPI (Sigma). Fluorescent images were obtained using a confocal laser-scanning microscope (FV-1000; Olympus, Tokyo, Japan) or a fluorescent microscope (BZ-9000, Keyence, Osaka, Japan). The total area and the number of LDs and the cell number (nuclear number) in each field of view were quantified by using Image-J software (http://imagej. nih.gov/ij/). The area occupied by a single LD was calculated as follows:
Total area occupied by LDs in a single cell The average size occupied by a single LD was calculated using data obtained from 15 fields of view.
Transmission electron microscopy Cells were cultured on cover glass slips coated with 0.1 mg ml À1 collagen. After 48 h incubation, cells on cover glass slips were fixed with 0.1 M phosphate buffer (pH 7.4) containing 2 % glutaraldehyde (Wako), 2 % paraformaldehyde and 0.5 % OsO 4 (Nisshin EM, Tokyo, Japan) for 1 h at 4 C. Ultra-thin sections were prepared under a monolayer condition for transmission electron microscopic analysis, according to a method described previously [42] . The resulting grids were observed using an H-7500 electron microscope (Hitachi High-Tech, Tokyo, Japan). The area occupied by a single LD was estimated using Image-J software. The average size occupied by an LD was calculated using data obtained from 30 cells.
Plasmid construction, transfection and immunoblotting
The genes encoding human CIDEB and CIDEC were amplified from HepG2 cDNA by PCR and then introduced to pEF pGKpuro FLAG [43] . The plasmids pUC19 HBV Ae_US, pUC19 HBV Bj_JPN35 and pUC19 HBV C_JPNAT [44] were kindly provided by Dr Masashi Mizogami. The plasmids were transfected into HepG2.2.15 cells using the GenJet-HepG2 in vitro transfection reagent (SignaGen, Gaithersburg, MD, USA), or into Huh7-OK1 cells using Tran-SIT LT1 reagent (Mirus Bio, Madison, WI, USA). Western blotting was carried out by a method described previously [45] . The cell lysates were subjected to SDS-12% polyacrylamide gel electrophoresis. The proteins transferred onto the membranes were reacted with horseradish peroxidase-conjugated antibody,and then visualized with the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL, USA). The stained bands were analysed using the image analyser LAS-4000 Mini (GE Healthcare, Tokyo, Japan).
Quantitative polymerase chain reaction (qPCR) and quantitative reverse transcription PCR (qRT-PCR) Total RNA was extracted using the RNeasy mini kit (QIA-GEN, Valencia, CA, USA), and this was followed by DNase digestion using the TURBO DNA-free kit (Ambion, Life Technologies). Total RNA (1 µg) was reverse-transcribed with the PrimeScript RT-PCR kit (Takara Bio, Kyoto, Japan) to prepare cDNA. DNA was purified from culture supernatant using the QIAamp DNA mini kit (QIAGEN). Viral DNA RNA and CIDE family mRNAs were estimated by real-time PCR using Fast SYBR Green Master Mix (Life Technologies). The amounts of viral DNA and intracellular viral RNA were estimated by qPCR or qRT-PCR using primer pairs 5'-TCAC-CAGCACCATGCAAC-3¢ and 5¢-AAGCCACCCAAGGCA-CAG-3¢. The amounts of CIDEA, CIDEB, CIDEC and GAPDH mRNAs were estimated by qRT-PCR using primer pairs 5¢-CATGTATGAGATGTACTCCGTGTC-3¢ and 5¢-GAGTAGGACAGGAACCGCAG-3, 5¢-AGCCAAAGCATT GGAGACCCTACT-3 and 5¢-TCTGACCAGACTGCAA-CACCATCA-3, 5¢-GCCTTCTCTACCCCAAGTCC-3 and 5¢-CAGGAAGAAGGGCTTGTCTG-3, and 5¢-GAAGGTCG GAGTCAACGGATT-3¢ and 5¢-TGATGACAAGCTTCCCG TTCTC-3¢, respectively. The fluorescent signals of real-time PCR were obtained and analysed via the StepOnePlus RealTime PCR System (Applied Biosystems, Life Technologies). Semi-quantitative RT-PCR was carried out using EmeraldAmp PCR Master Mix (Takara Bio). The resulting PCR products were subjected to 2 % agarose gel electrophoresis.
Knockdown of HBV in HepG2.2.15 cells
The siRNA targeted to HBV (ID:B1789) reported by Zhang et al. [46] was synthesized by Nippon Gene (Tokyo, Japan). The non-targeting control siRNA (siControl Non-targeting siRNA #2, Dharmacon) was purchased from Thermo Scientific. These siRNAs were introduced at a final concentration of 10 nM into HepG2.2.15 cells using Lipofectamine RNAiMax (Life Technologies). The resulting cells were harvested 72 h post-transfection.
Luciferase reporter assay for promoter activity The promoter regions of CIDEB and CIDEC genes were reported previously [32, 47] . DNA fragments corresponding to the regions spanning from À204th to À1 st and À269th to À1 st on the upstream region of cideb and cidec, respectively, were amplified by PCR and then introduced into pGL4.18-basic. The plasmids encoding cideb and cidec promoters were designated as pGL4.18-cideb and pGL4.18-cidec, respectively. DNA fragments of the core upstream regulatory sequence (CURS) and basic core promoter (BCP) were amplified from the Ae_US strain and then cloned into pGL4.18 (Promega) for estimation of the HBV core-promoter activity [30] . Firefly luciferase activity was evaluated as promoter activity and normalized with Renilla luciferase activity derived from the co-transfected plasmid pRL-TK obtained from Promega (Madison, WI, USA).
Preparation of CIDEB-and CIDEC-deficient HepG2.2.15 cell lines CIDEB-and CIDEC-deficient HepG2.2.15 cell lines were prepared according to the method reported by Fujihara et al. [48] . Plasmids pX330 and pCAG EGxxFP were obtained from Addgene (plasmids #42230 and #50716; Cambridge, MA, USA) [48] . The targeting sequences of cideb and cidec were 5¢-CCAGTGACTTACTCAGTGACTGC-3¢ and 5¢-CCATGAAGTCCCTTAGCCTTCTC-3', respectively, for construction of the plasmids encoding guide RNAs. The targeting DNA regions were amplified from the genomic DNA of HepG2.2.15 using the primer pairs 5¢-ACTGAGGAT CCTACATGGTTCCCATCTACCCTCAC-3¢ and 5¢-GAT ATCGAATTCTGTGGCTCAGGAGCTTGACAAG-3¢, and 5¢-ACTGAGGATCCGTCTTGGTTGGCATGCATGGG-3¢ and 5¢-GATATCGAATTCGGAGTAAAAGCACCAAGC ATAGTGT-3¢, for CIDEB and CIDEC, respectively, and then introduced into pCAG EGxxFP. HepG2.2.15 cells were transformed with these plasmids and then cultivated for 7 days. GFP-positive cells were isolated by limited dilution and colony isolation. Gene-knockout regions were confirmed by direct sequencing. The deleted regions of each allele of cideb or cidec were confirmed by direct sequencing. Expressions of CIDEB and CIDEC were confirmed by immunoblotting analysis.
Estimation of HBs antigen, HBe antigen and TG
The amount of HBs and HBe antigens in the culture supernatant was estimated using a chemiluminescent immunoassay (SRL Inc., Tokyo, Japan). The amount of intracellular TG was quantified using the Triglyceride Quantification colorimetric/Fluorometric kit (Bio Vision, Milpitas, CA, USA) according to the instruction manual.
Statistical analysis
Data are shown as the mean ± standard deviation (SD). The significance of the differences between two groups was determined using Student's t-test.
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